Open AccessA Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
Author(s) -
Ignacio Basurte-Villamor,
Pablo Barranco Vega,
Carlos Roncero,
José Martı́nez-Raga,
Lara Grau-López,
Lourdes Aguilar,
Marta Torrens,
Néstor Szerman
Publication year - 2022
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s358782
Subject(s) - vortioxetine , medicine , major depressive disorder , clinical global impression , depression (economics) , psychiatry , quality of life (healthcare) , rating scale , cognition , psychology , alternative medicine , nursing , pathology , economics , macroeconomics , placebo , developmental psychology
Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD.